Cargando…
Forty-nine-month survival in a metastatic renal cell carcinoma patient across six lines of targeted therapy
A better understanding of the aetiopathogenetic molecular targets in renal cell carcinoma (RCC) and the subsequent advent of targeted therapeutic agents have greatly improved the management and prognosis of RCC and patient survival. However, optimising therapeutic outcomes through appropriate sequen...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cancer Intelligence
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932807/ https://www.ncbi.nlm.nih.gov/pubmed/24624226 http://dx.doi.org/10.3332/ecancer.2014.406 |